Hainan Zhonghe Pharmaceutical Co., Ltd.

Established on April 17, 1995, Hainan Zhonghe Pharmaceutical Co., Ltd. is China’s first high-tech pharmaceutical manufacturer specializing in the research and production of chemically synthesized peptide drugs, APIs and skin care prodcuts. A pioneer in the Chinese peptide industry, Zhonghe developed and launched the nation’s first modern peptide drug—Thymopentin for Injection—marking a historic milestone in domestic peptide therapeutics. 

With a provincial-grade peptide drug R&D center, Zhonghe drives innovation through the independent development of novel peptide, and nucleoside drugs. Our diverse pipeline spans multiple therapeutic areas, including immunology, oncology, hepatology, emergency medicine, gastroenterology, urology, cardiovascular diseases, gynecology, and perinatology. 

Equipped with cutting-edge technology and large-scale production capabilities, Zhonghe stands as China’s foremost peptide drug manufacturer. Quality is our cornerstone—supported by a rigorous, regulatory-compliant QC/QA system, our facilities have earned GMP certifications from China’s NMPA and Korea’s MFDS (a PIC/S member), ensuring global standards. 

Through superior product quality and professional commercialization, Zhonghe has built a strong market presence, with a sales network covering China and expanding internationally—including South Korea, Uzbekistan, and others. Our products are approved in Hong Kong, Macao, Mongolia, Chile, Pakistan, and the Philippines, with ongoing registrations in Thailand, Sri Lanka, Peru, Paraguay, and Saudi Arabia. 

Zhonghe Pharmaceutical is committed to advancing peptide therapeutics worldwide, delivering life-changing treatments to patients and partners across the globe.